ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
NYSE:ADCT
Price:
4.72 USD
-0.84%
Market Closed
Updated:
Apr 20, 2024
ADC Therapeutics SA
Capital Expenditures
Last
Value
3-Years CAGR
5-Years CAGR
|
ADC Therapeutics SA
Capital Expenditures Peer Comparison
Comparables:
ACIU
CRSP
BSLN
IDIA
KURN
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Capital Expenditures
$-2.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Capital Expenditures
CHf-801k
|
CAGR 3-Years
22%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Capital Expenditures
$-12m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Capital Expenditures
CHf-1m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
1%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Capital Expenditures
CHf-27.1m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Capital Expenditures
CHf-326k
|
CAGR 3-Years
-14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Capital Expenditures?
Capital Expenditures
-2.3m
USD
-2.3m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Capital Expenditures amounts to -2.3m USD.
What is ADC Therapeutics SA's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
1%
1%
Over the last year, the Capital Expenditures growth was 0%. The average annual Capital Expenditures growth rates for ADC Therapeutics SA have been 6% over the past three years , 1% over the past five years .
You don't have any saved screeners yet
